In the News
powered by Ovast-
FDA: Revlimid Linked To Second Cancers - MedPage Today
google.com 3 weeks, 1 day agoFDA: Revlimid Linked to Second Cancers MedPage Today By Michael Smith, North American Correspondent, MedPage Today Treatment of multiple myeloma with lenalidomide (Revlimid) as maintenance therapy is associated with an increased risk of second primary cancers, the FDA warned. In three trials involving ... FDA warns of malignancy risk with Revlimid FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers FDA Issues Extensive Update About Revlimid And Second Cancers -
-
New Drug Shows Promise For Myeloma Patients
yahoo.com 3 weeks agoWEDNESDAY, May 9 (HealthDay News) -- Three new studies confirm that the drug lenalidomide can significantly lengthen the time that people with multiple myeloma experience no worsening of their disease, either after having a stem cell transplant or...


Loading More Stories